ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. / Montalban, Xavier; Gold, Ralf; Thompson, Alan J; Otero-Romero, Susana; Amato, Maria Pia; Chandraratna, Dhia; Clanet, Michel; Comi, Giancarlo; Derfuss, Tobias; Fazekas, Franz; Hartung, Hans Peter; Havrdova, Eva; Hemmer, Bernhard; Kappos, Ludwig; Liblau, Roland; Lubetzki, Catherine; Marcus, Elena; Miller, David H; Olsson, Tomas; Pilling, Steve; Selmaj, Krysztof; Siva, Axel; Sorensen, Per Soelberg; Sormani, Maria Pia; Thalheim, Christoph; Wiendl, Heinz; Zipp, Frauke.
I: Multiple Sclerosis Journal, Bind 24, Nr. 2, 2018, s. 96-120.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
AU - Montalban, Xavier
AU - Gold, Ralf
AU - Thompson, Alan J
AU - Otero-Romero, Susana
AU - Amato, Maria Pia
AU - Chandraratna, Dhia
AU - Clanet, Michel
AU - Comi, Giancarlo
AU - Derfuss, Tobias
AU - Fazekas, Franz
AU - Hartung, Hans Peter
AU - Havrdova, Eva
AU - Hemmer, Bernhard
AU - Kappos, Ludwig
AU - Liblau, Roland
AU - Lubetzki, Catherine
AU - Marcus, Elena
AU - Miller, David H
AU - Olsson, Tomas
AU - Pilling, Steve
AU - Selmaj, Krysztof
AU - Siva, Axel
AU - Sorensen, Per Soelberg
AU - Sormani, Maria Pia
AU - Thalheim, Christoph
AU - Wiendl, Heinz
AU - Zipp, Frauke
PY - 2018
Y1 - 2018
N2 - BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.
AB - BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.
U2 - 10.1177/1352458517751049
DO - 10.1177/1352458517751049
M3 - Journal article
C2 - 29353550
VL - 24
SP - 96
EP - 120
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
IS - 2
ER -
ID: 216467645